• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology

    2019-11-05 03:31:32AngelaMweempwaMichelleWilson
    Cancer Drug Resistance 2019年3期

    Angela Mweempwa,Michelle K.Wilson

    Cancer and Blood,Auckland City Hospital,Auckland 1023,New Zealand.

    Abstract

    Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) lead to synthetic lethality when used in cancers harbouring a BRCA mutation or homologous recombination deficiency.There are now four PARPi approved by the Food and Drug Administration for therapeutic use is ovarian and breast cancer.In addition to this,there is data supporting its use in pancreatic adenocarcinoma and prostate cancer.However,development of resistance to PARPi limits the duration of response.Key mechanisms found to date include:(1) restoration of homologous recombination; (2) changes in PARP1; (3) suppression of non-homologous end joining; (4) replication fork protection; and (5) drug concentration.Gaining a better understanding of resistance mechanisms may guide combination therapies to overcome the resistance and improve the efficacy of PARPi.The purpose of this review is to describe the resistance mechanisms to PARPi and discuss their early detection.

    Keywords: Poly-adenosine diphosphate ribose polymerase inhibition,resistance mechanisms,homologous recombination,BRCA reversion,ovarian cancer

    INTRODUCTION

    Poly-adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors are now part of mainstream therapy for cancers harbouring BRCA mutations as well as other deficiencies in homologous recombination (HR) repair[1-6].Since 2014,four PARP inhibitors (PARPi) have been approved in the United States:olaparib,niraparib,rucaparib and talazoparib[3,5,7-12][Table 1].Olaparib was the first FDA approved PARPi,initially for recurrent ovarian carcinoma with a germline BRCA mutation exposed to at least 3 lines oftherapy and subsequently as maintenance therapy for women with germline BRCA mutations and patients with breast cancer with germline BRCA mutations[1,2,5,7-9].Veliparib was awarded orphan drug designation for squamous non-small cell lung cancer[13].Although veliparib is the least potent of the PARPi currently in use,there are multiple combination trials in progress such as the S1416 study (NCT02595905)[14].Pamiparib is another PARPi under investigation in a number of clinical trials[15-17].

    Table 1.Current FDA approved PARP inhibitors

    Talazoparib has the greatest PARP trapping activity (rank from highest:talazoparib > niraparib > olaparib = rucaparib > veliparib) and is the most potent among the PARPi in current use[14,18].

    Although nausea,fatigue and anaemia are common to all PARPi,some differences in the toxicity profiles have been observed.Thrombocytopenia is more prominent with niraparib,with grade 3 or 4 reductions in platelet counts occurring in a third of treated patients[3].A retrospective analysis has shown that modifying the dose of niraparib based on baseline body weight and platelet counts may reduce the degree of thrombocytopenia[19].Elevated serum creatinine has been observed with olaparib in 11% of patients whereas both rucaparib and niraparib have been reported to cause an increase in alanine aminotransferase or aspartate aminotransferase[5,10].

    The interest in these agents has expanded and is now being explored in many different cancer types including prostate and pancreatic cancer[20,21].Because the likelihood of relapse is high in these patient populations,defining the mechanisms promoting resistance,and subsequent therapeutic failure remains extremely important.This paper will present the current literature on this.

    MECHANISM OF ACTION OF PARPi

    PARPs are a superfamily of 17 enzymes involved in a multitude of intracellular processes including DNA damage repair,replication and transcription.PARP1 and PARP2 are constitutively expressed but only become activated on binding to sites of DNA damage.PARP1 and PARP2 use nicotinamide adenine dinucleotide (NAD+) as a substrate to transfer ADP-ribosyl groups onto acceptor proteins and produce long poly(ADP-ribose) (PAR) chains in a process called PARylation[22].PARylation of core histones exerts a negative charge and leads to relaxation of chromatin and recruitment of transcription proteins[23].Auto-PARylation of PARP1 and PARP2 permits their dissociation from DNA,a step required for the repair proteins to access damaged DNA[24,25].PARylation is counteracted by the activity of PAR glycohydrolase (PARG)[26].

    PARP1,the most abundant of the PARPs,recognizes DNA single-strand breaks and repairs them by base excision repair (BER).PARPi suppress BER leading to stalling of the replication fork and subsequent development of double-strand breaks (DSBs).In BRCA proficient cells,DSBs are repaired by HR.HR is a DNA repair mechanism that utilises a homologous chromosome or sister chromatid as a template for repair of the damaged portion of DNA[24].During HR,BRCA1 promotes the 5' to 3' resection of DSB with the involvement of nucleases such as MRE11,carboxy-terminal binding protein interacting protein (CtIP) and exonuclease 1,leaving a 3' overhang onto which BRCA2 loads RAD51,enabling invasion of a sister chromatid to be used as a template for DNA repair[27].As a result,this repair pathway is precise and errorfree[24].In contrast,DSBs in BRCA deficient cells are repaired by non-homologous end joining (NHEJ),a process inherently prone to errors as it involves removal of the section containing damaged DNA and ligation of the ends which leads to loss of DNA sequence[24].Errors resulting from NHEJ lead to genomic instability,cell cycle arrest and apoptosis[28].It is widely known that inhibiting PARP in the setting of a BRCA mutation leads to synthetic lethality since it is the combination of a PARPi and BRCA deficiency that induces lethality[29][Figure 1].

    Two mechanisms of action of PARPi have been described.PARPi competitively bind to the NAD+ site of PARP1 and PARP2 resulting in inhibition of their catalytic activity[14,30].When this occurs there is a failure of auto-PARylation of PARP leading to PARP trapping,which may be the main mechanism of action of some PARPi such as talazoparib[31].Although the efficacy of PARPi is higher in cancers with BRCA mutations or HR deficiency (HRD),it is known that they can be beneficial to patients with wild-type BRCA and in the absence of HRD[3].

    RESISTANCE MECHANISMS

    While BRCA 1/2 mutations remain the strongest markers of PARPi sensitivity[3],40%-70% of this patient cohort will fail to respond[32-34].To date,several mechanisms of resistance have been described including :(1) restoration of HR; (2) changes in PARP1; (3) suppression of NHEJ; (4) replication fork protection; and (5) drug concentration [Figure 2].The most common acquired mechanism of resistance appears to be the restoration of BRCA1 or BRCA2 protein function as a result of secondary mutations[28].

    MECHANISMS OF RESISTANCE RELATED TO RESTORATION OF HOMOLOGOUS RECOMBINATION

    There are multiple different pathways that lead to the restoration of HR function.BRCA1 or BRCA2 protein functionality can be restored through the development of intragenic mutations or epigenetic reversions that lead to activation of the open reading frame[27].It is recognised that 46% of recurrent platinum-resistant epithelial ovarian carcinoma develop secondary somatic mutations restoring BRCA1/2 function[35].Additionally,overexpression of BRCA driven by copy number gain and/or upregulation of the remaining functional allele has been shown in tumours with somatic loss of BRCA[36].

    Furthermore,de novointrachromosomal genomic BRCA1 rearrangements and promoter demethylation leading to re-expression of BRCA1 have been demonstrated in PDX models and post-treatment biopsies of triple-negative breast cancer patients,respectively[37].Promoter demethylation may also arise from a heterogeneous tumour in which cells with less promoter methylation undergo positive selection with exposure to PARPi[27].

    Additionally,other proteins involved in the DNA repair process may restore HR.Illustrating this,53BP1 works in close relation with BRCA1 balancing HR and NHEJ repair pathways.53BP1 commits DNA repair to classical-NHEJ by blocking CtIP-mediated DNA end resection[27].The loss of 53BP1 in BRCA deficient cells leads to resection of DNA double-stranded breaks prompting RAD51 recruitment and restoration of HR[38].More recently,new DNA repair factors,including RINN1,RINN2 and RINN3,have been identified which interact with REV7 to form the shieldin complex[39-41].It has been proposed that shieldin functions as a downstream effector of 53BP1-RIF1 in the DNA double-stand break repair pathway,preventing DNA end resection and thus,promoting NHEJ[39].Deletion of any components of the shieldin complex confers resistance to PARPi in BRCA1-mutant cells by re-establishing end resection and restoring HR[28,39].

    Figure 2.Mechanisms of PARPi resistance.A:Efflux of PARP inhibitors by P-gp pumps may contribute to resistance by reducing the intracellular PARPi concentration; B:PARP1 deletion or point mutations in PARP1 reduce sensitivity to PARPi.PARG suppression restores downstream PARP1 signalling with PARPi therapy; C:loss of expression of PTIP,EZH2,MUS81 or increased miR-493-5p results in stabilization of the replication fork,leading to PARPi resistance; D:deficiency of 53BP1,RIF1,REV7 and RINN1-3 involved in the regulation of DNA end-resection during DNA repair may induce PARPi resistance; E:overexpression of miR-622 suppresses NHEJ and rescues the homologous recombination deficiency of BRCA mutated cells.Modified from Thomas et al.[30].PARP1:poly(ADP) ribose polymerase 1; NAD:nicotinamide adenine dinucleotide; PARG:poly(ADP) ribose glycohydrolase; HR:homologous recombination; NHEJ:nonhomologous end joining; DNA:deoxyribonucleic acid

    RAD51 is another protein that plays a key role in HR repair.It is loaded onto single-stranded and doublestranded DNA by BRCA2 to form a protective filament against nucleases[42].An increase in RAD51 will promote HR and subsequently,resistance to PARPi[43].RAD51C and RAD51D are RAD51 paralogs that also play an essential role in DNA repair through HR.The presence of a germline mutation in RAD51C and RAD51D predisposes women to ovarian cancer and is associated with PARPi sensitivity[44].Secondary mutations in RAD51C and RAD51D lead to the restoration of the open reading frame,allowing HR function to proceed which contributes to the development of PARPi resistance[44].PTEN loss in the setting of BRCA1 mutation is another mechanism that leads to reversal of HR deficiency[45].

    Acute myeloid leukaemia driven by transcription factors,AML1-ETO and PML-RARα fusion oncoproteins,is sensitive to PARPi due to suppressed HR and compromised DNA damage response[46].It has been shown that overexpression of the myeloid leukaemia-associated HOXA9 gene in AML1-ETO and PML-RARαtransformed cells enhances HR efficiency leading to PARPi resistance[46].

    Schlafen 11 (SLFN11) expression is another factor that has been shown to correlate with PARPi sensitivity[47,48].It has been suggested that SLFN11 inhibits replication by inducing prolonged cell cycle arrest at S-phase after PARPi treatment,whereas SLFN11-deficient cells are able to continue replicating,resulting in PARPi resistance[47].It is likely over the next 5 years,more genes involved in this process will become recognised as evidence arises.

    RESISTANCE MECHANISMS RELATED TO PARP1

    PARP1 is the most abundant of the PARPs but while it plays a role in multiple intracellular processes,it is not essential to cell survival and PARP1 deletion does not lead to cell death[24].It has been shown that PARP1 deletion leads to partial PARPi resistance,rather than complete because PARP trapping is not the sole mechanism of PARPi action[24,49].Specific point mutations,however,can lead to PARPi resistance as shown withde novoresistance to Olaparib in a patient with ovarian cancer[50].Additionally,PARP1 phosphorylation at Tyr907 by tyrosine kinase c-Met increases PARP1 catalytic activity and reduces binding affinity to PARPi leading to PARPi resistance[51].

    PARG plays a vital role in the degradation of nuclear PAR,preventing its accumulation and counteracting the effects of PARP1[26].It is now recognized that PARG depletion is associated with PARPi resistance in HR deficient tumours by restoring PARP1 signalling[26].

    It remains controversial as to whether overexpression of PARP1 leads to resistance to PARPi.Earlier data suggested that it did lead to resistance resulting in increased PARPi concentrations required to inhibit the enzyme[52].This is in contrast to a retrospective analysis of BRCA1 and PARP1 expression in epithelial ovarian cancer patients that showed no correlation between survival and PARP1 expression[53].

    Suppression of NHEJ

    As described earlier,DSBs can be repaired by NHEJ or HR[24].The balance between HR and classical NHEJ (C-NHEJ) is maintained by miR-622,which limits C-NHEJ and promotes HR.Overexpression of miR-622 is associated with decreased expression of genes such as 53BP1,Ku70,and Ku80[54].The Ku complex normally diverts DNA damage response to the C-NHEJ pathway,therefore its decreased expression will lead to activation of HR by the accumulation of MRE11 foci at the sites of DSBs.This rescues the HR deficiency of BRCA1 mutated cells and induces resistance to PARPi[54].

    Replication fork protection

    BRCA1 and BRCA2 play a critical role in replication fork protection.BRCA1 promotes end resection of DSBs enabling BRCA2 to load RAD51 onto the exposed DNA strands,thus protecting the replication fork from MRE-mediated degradation[27].Stabilization of the replication fork induces alternate mechanisms of DNA repair resulting in PARPi resistance[24].Pax2 transactivation domain-interacting protein (PTIP) is a DNA damage response protein that is required to recruit MRE11 nuclease for replication fork degradation.Deficiency of PTIP impedes the recruitment of the MRE11 nuclease to stalled replication forks,which in turn protects nascent DNA strands from extensive degradation[55].As a result,there is a reduced level of chromosomal aberrations in BRCA1/2 deficient cells,leading to genomic stability and drug resistance[55].

    There is also work demonstrating that EZH2,a histone methyl-transferase,plays a role in replication fork degradation by recruiting nuclease MUS81 to the stalled fork[56].Therefore,loss of expression of EZH2 or MUS81 will lead to PARPi resistance due to the resulting fork stabilization[56].A mi-RNA has been identified,miR-493-5p,that downregulates MRE11,CHD4 and EXO1 in BRCA2 mutant cells and by doing so,preserves replication fork stability[42].It is interesting to note that these mechanisms of resistance leading to replication fork stabilization do not restore HR[42,55,56].

    Drug concentration

    Drug concentration of the PARP inhibitor may play a role.The p-glycoproteins (P-gp),also called multidrug resistance proteins are involved in the efflux of PARPi.Upregulation of ATP-dependent efflux pumpABCB1(MDR1) gene,which encodes for P-glycoprotein,a multidrug efflux transporter,can lead to resistance to some PARPi due to their enhanced extracellular translocation[57].P-gp inhibitors have been shown to prevent the decrease of PARPi in colon cancer cells[58]and re-sensitize PARPi-resistant BRCA-1 deficient cells to PARPi[59].In the mouse models,PARPi was more effective when P-gp knockout conditions were added to BRCA-1 deficient cells[60].More work is needed in this domain because the resistance to PARPi via upregulation of P-gp has mainly been demonstrated in cell and animal models[61].

    Detecting resistance

    Different methods to detect markers of resistance have been explored.Spatial and temporal heterogeneity is a challenge facing personalised medicine in oncology.Ongoing studies are underway exploring the impact of subclonal populations on tumour biology and progression.Serial tumour sampling to monitor clonal evolution poses practical challenges and is currently not standard practice.An alternative approach under investigation is the use of “l(fā)iquid biopsies”,whereby circulating cell-free tumour DNA (cfDNA) or circulating tumour cells (CTCs) are analysed in the peripheral blood of patients with cancer[62].

    The value of cfDNA and serial samples has been investigated in five patients with ovarian cancer with intragenic mutations predicted to restore BRCA1/2 open reading frames,including two patients with multiple independent reversion alleles[63].Reversion mutations were detected only in tumour samples from patients with recurrent disease (5 of 16) and only in cfDNA from three of five patients with a tumourdetected reversion.In this study,findings from a rapid autopsy of one patient with multiple independent reversions demonstrated that reversion-allele frequency in metastatic sites is an important determinant of assay sensitivity.Research continues in this area[63].

    It is important this field continues to be explored and practical methods to delineate mechanisms of resistance continue to be tested such as cfDNA if patient outcomes are to improve.In lung cancer,therapeutic advances have continued to be made for patients with EGFR mutations through improved understanding of the mechanisms of resistance to first-generation tyrosine kinase inhibitors such as erlotinib and the subsequent development of agents specific to the identified mechanisms.This may be more challenging due to the large number of potential mechanisms of resistance to PARPi.Ongoing trials such as the NEO study (NCT03548467) are looking to better identify this.This study uses a window of opportunity design to better delineate predictors of response and resistance to PARPi alongside the use of circulating tumour DNA.ARIEL 2,a phase 2 trial investigating rucaparib in relapsed,platinum sensitive high grade ovarian carcinoma,included the collection of biopsies at relapse to also help delineate this[64].Discovering more about this and identifying practical ways to assess this will help improve care for these patients.

    Overcoming resistance

    The main cause of resistance appears to be through the restoration of HR.Due to the complexity of this pathway,there are multiple changes beyond the restoration of the BRCA1/2 protein that contribute to this.Addition of agents that disrupt HR such as CDK12,CDK1 and PI3K inhibitors are some of the strategies being investigated to overcome this resistance[27].Furthermore,a clinical trial (NCT03742245) has been designed to assess the synergism between histone deacetylase inhibitors and PARPi in BRCA deficient cells[65].Combination with an ATR inhibitor overcomes PARPi resistance resulting from SLFN11 inactivation and is currently being evaluated in a phase I study (NCT02723864)[47].

    There is a host of other clinical trials in progress looking at alternative strategies to maintain sensitivity to PARPi,such as concurrent inhibition of WEE1,VEGFR and mTOR pathways[66].WEE1 is a cell cycle regulator that promotes reversible cell cycle arrest to facilitate DNA repair.WEE1 inhibitors cause the cells to enter S phase with unrepaired DNA and when used in conjunction with PARPi therapy,may mitigate PARPi resistance[66].

    Inhibition of angiogenesis with VEGFR inhibitors induces hypoxia in the tumour microenvironment leading to decreased expression of HR repair proteins and therefore enhanced effects of PARPi therapy[67].Phase 3 trials are in progress exploring this strategy in ovarian cancer by combining olaparib and cediranib,a pan-VEGFR inhibitor (NCT02446600 and NCT02502266).In addition,it has been demonstrated that mTOR inhibitors suppress HR repair and synergize with PARPi which may be another approach to preserve PARPi sensitivity[68].

    CONCLUSION

    PARPi have led to improved outcomes in a several tumour types.The importance of HR deficiency is one key factor in predicting patients that are more likely to be sensitive.The likelihood of relapse remains high in these patient populations,and hence defining the mechanisms promoting resistance,and subsequent therapeutic failure remains extremely important.Gaining an understanding of resistance mechanisms may guide combination therapies to overcome resistance.Choosing the best treatment option following the development of resistance to PARPi remains a challenge.Multiple signatures may predict responders and also non-responders.Given the complexity,ongoing research will help better delineate the cohorts that benefit and help define therapies that overcome resistance pathways.

    DECLARATIONS

    Authors' contributions

    Both authors contributed equally to the article.

    Availability of data and materials

    Not applicable.

    Financial support and sponsorship

    None.

    Conflicts of interest

    Wilson MK has travel support from MSD and Roche,Mweempwa A has travel support from Roche.

    Ethical approval and consent to participate

    Not applicable.

    Consent for publication

    Not applicable.

    Copyright

    ?The Author(s) 2019.

    色综合色国产| 一区二区三区免费毛片| 国产亚洲精品久久久com| 成人亚洲精品av一区二区| 美女被艹到高潮喷水动态| 免费无遮挡裸体视频| 人人妻,人人澡人人爽秒播| 亚州av有码| 精品免费久久久久久久清纯| 色视频www国产| 看片在线看免费视频| 国产高清不卡午夜福利| 一a级毛片在线观看| 国产亚洲91精品色在线| 日韩高清综合在线| 中文在线观看免费www的网站| 黄色一级大片看看| 神马国产精品三级电影在线观看| 18禁黄网站禁片免费观看直播| 国产成人freesex在线 | 综合色av麻豆| 91久久精品国产一区二区三区| 亚洲最大成人av| а√天堂www在线а√下载| 性插视频无遮挡在线免费观看| 美女cb高潮喷水在线观看| 亚洲国产色片| 中文字幕精品亚洲无线码一区| 亚洲av不卡在线观看| 精品久久久噜噜| 国产精品亚洲美女久久久| 成人亚洲欧美一区二区av| 男女下面进入的视频免费午夜| 搡老妇女老女人老熟妇| 国产精品久久电影中文字幕| 亚洲色图av天堂| 欧美日韩精品成人综合77777| 偷拍熟女少妇极品色| 秋霞在线观看毛片| 国产伦一二天堂av在线观看| 婷婷色综合大香蕉| 成人午夜高清在线视频| 欧美成人精品欧美一级黄| 欧美+日韩+精品| 神马国产精品三级电影在线观看| 精品免费久久久久久久清纯| 国产久久久一区二区三区| 少妇高潮的动态图| 久久久久久伊人网av| 天天躁日日操中文字幕| 十八禁国产超污无遮挡网站| 国内少妇人妻偷人精品xxx网站| 国产av不卡久久| 毛片女人毛片| 极品教师在线视频| 亚洲av免费高清在线观看| 看非洲黑人一级黄片| 久久精品国产自在天天线| av中文乱码字幕在线| 日本五十路高清| 日韩精品有码人妻一区| 天堂动漫精品| 亚洲欧美日韩卡通动漫| 一本一本综合久久| 蜜桃亚洲精品一区二区三区| 老师上课跳d突然被开到最大视频| 看黄色毛片网站| av福利片在线观看| 国产三级中文精品| 久久久成人免费电影| 中文字幕熟女人妻在线| 日本欧美国产在线视频| 久久99热6这里只有精品| 国产在线男女| 久久国产乱子免费精品| 亚洲精品久久国产高清桃花| 人妻丰满熟妇av一区二区三区| 亚洲一区二区三区色噜噜| 亚洲精品色激情综合| 久久九九热精品免费| 啦啦啦观看免费观看视频高清| 国产女主播在线喷水免费视频网站 | 又粗又爽又猛毛片免费看| 国产精品日韩av在线免费观看| 精品人妻熟女av久视频| 国产成人freesex在线 | 啦啦啦观看免费观看视频高清| 两个人的视频大全免费| 亚洲性夜色夜夜综合| 夜夜夜夜夜久久久久| 国产伦一二天堂av在线观看| 91麻豆精品激情在线观看国产| 99久久精品国产国产毛片| 成人美女网站在线观看视频| 久久精品人妻少妇| 一区二区三区四区激情视频 | 老司机福利观看| 91在线观看av| 精品熟女少妇av免费看| 99在线人妻在线中文字幕| 久99久视频精品免费| 国产亚洲精品综合一区在线观看| 少妇丰满av| 精品久久国产蜜桃| 1024手机看黄色片| 一个人看视频在线观看www免费| 国产不卡一卡二| 亚洲欧美日韩卡通动漫| 亚洲av成人精品一区久久| 身体一侧抽搐| 综合色丁香网| 国产大屁股一区二区在线视频| 成年女人看的毛片在线观看| 激情 狠狠 欧美| 免费看日本二区| 亚洲经典国产精华液单| 九色成人免费人妻av| 久久精品国产亚洲网站| 亚洲专区国产一区二区| 国产精品日韩av在线免费观看| 久久九九热精品免费| 卡戴珊不雅视频在线播放| 激情 狠狠 欧美| 国产成人a∨麻豆精品| eeuss影院久久| 91久久精品电影网| 色吧在线观看| 亚洲欧美日韩卡通动漫| aaaaa片日本免费| 亚洲人成网站在线观看播放| 日韩国内少妇激情av| 精品一区二区三区视频在线观看免费| 亚洲精品一区av在线观看| 97在线视频观看| 成人无遮挡网站| 成熟少妇高潮喷水视频| 免费看光身美女| 3wmmmm亚洲av在线观看| 亚洲欧美日韩卡通动漫| 国产精品久久久久久久久免| 搡老熟女国产l中国老女人| 国产精品一区二区三区四区免费观看 | 国产伦一二天堂av在线观看| 亚洲欧美精品自产自拍| 国产高清视频在线观看网站| 嫩草影院新地址| 久久久精品94久久精品| 嫩草影院入口| 国产精品伦人一区二区| 中文字幕av在线有码专区| 人人妻人人澡欧美一区二区| 中国国产av一级| 狂野欧美白嫩少妇大欣赏| 免费一级毛片在线播放高清视频| 夜夜看夜夜爽夜夜摸| 精品一区二区免费观看| 日本爱情动作片www.在线观看 | 精品一区二区三区视频在线观看免费| 亚洲真实伦在线观看| 高清日韩中文字幕在线| 欧美日韩乱码在线| 夜夜夜夜夜久久久久| 伦精品一区二区三区| av在线观看视频网站免费| 成人漫画全彩无遮挡| 国产日本99.免费观看| 日韩在线高清观看一区二区三区| 天天躁夜夜躁狠狠久久av| 色综合站精品国产| 在线免费十八禁| 99久久成人亚洲精品观看| 国产精品不卡视频一区二区| 日本与韩国留学比较| 亚洲av一区综合| 麻豆国产av国片精品| 99热精品在线国产| 日产精品乱码卡一卡2卡三| 我要搜黄色片| 极品教师在线视频| 亚洲精品一卡2卡三卡4卡5卡| 国产精品久久久久久精品电影| 最后的刺客免费高清国语| 国产乱人偷精品视频| 你懂的网址亚洲精品在线观看 | 亚洲精品456在线播放app| 国产欧美日韩精品一区二区| 国内精品美女久久久久久| 日韩欧美一区二区三区在线观看| av卡一久久| 热99re8久久精品国产| 内地一区二区视频在线| 久久久久国产精品人妻aⅴ院| 国产女主播在线喷水免费视频网站 | 搡老熟女国产l中国老女人| 91久久精品电影网| АⅤ资源中文在线天堂| 国内精品宾馆在线| 淫妇啪啪啪对白视频| 高清午夜精品一区二区三区 | 97在线视频观看| 亚洲人与动物交配视频| 啦啦啦韩国在线观看视频| 免费观看在线日韩| 香蕉av资源在线| 最近手机中文字幕大全| 亚洲第一电影网av| 自拍偷自拍亚洲精品老妇| videossex国产| 天堂av国产一区二区熟女人妻| 一区福利在线观看| 美女 人体艺术 gogo| 黄色日韩在线| 免费大片18禁| 亚洲av中文字字幕乱码综合| 色吧在线观看| 九九爱精品视频在线观看| 一区二区三区高清视频在线| 亚洲精品久久国产高清桃花| 又黄又爽又免费观看的视频| 国国产精品蜜臀av免费| 国产 一区 欧美 日韩| 日产精品乱码卡一卡2卡三| 俺也久久电影网| 久久久久免费精品人妻一区二区| 十八禁网站免费在线| 国产v大片淫在线免费观看| 1000部很黄的大片| 中文在线观看免费www的网站| 国产女主播在线喷水免费视频网站 | 久久久欧美国产精品| 色综合亚洲欧美另类图片| 久久久久性生活片| 寂寞人妻少妇视频99o| 国产成人福利小说| 十八禁国产超污无遮挡网站| 久久99热这里只有精品18| 午夜激情欧美在线| 亚洲一区二区三区色噜噜| av视频在线观看入口| 国产精品电影一区二区三区| 免费不卡的大黄色大毛片视频在线观看 | 婷婷精品国产亚洲av| 有码 亚洲区| 国内久久婷婷六月综合欲色啪| 欧美日本亚洲视频在线播放| 最近的中文字幕免费完整| 黄色配什么色好看| 美女xxoo啪啪120秒动态图| 日本一本二区三区精品| 精品一区二区免费观看| 国产91av在线免费观看| 一级a爱片免费观看的视频| 国产欧美日韩一区二区精品| 在线天堂最新版资源| 91在线精品国自产拍蜜月| 免费一级毛片在线播放高清视频| 五月玫瑰六月丁香| 久久人妻av系列| 日本色播在线视频| 国产精品一二三区在线看| 久久精品91蜜桃| 狠狠狠狠99中文字幕| av专区在线播放| 97人妻精品一区二区三区麻豆| 乱系列少妇在线播放| 波野结衣二区三区在线| 亚洲av第一区精品v没综合| 日韩大尺度精品在线看网址| av天堂在线播放| 校园人妻丝袜中文字幕| 国产视频内射| 国产午夜精品论理片| 黄片wwwwww| 亚洲美女黄片视频| 久久久精品欧美日韩精品| 午夜激情欧美在线| 伊人久久精品亚洲午夜| 日本精品一区二区三区蜜桃| 99热这里只有是精品在线观看| 波野结衣二区三区在线| 有码 亚洲区| 欧美成人免费av一区二区三区| 欧美三级亚洲精品| 国产精品爽爽va在线观看网站| 九九爱精品视频在线观看| 一区二区三区高清视频在线| 长腿黑丝高跟| 日本欧美国产在线视频| 看黄色毛片网站| 色综合亚洲欧美另类图片| 精品无人区乱码1区二区| 老熟妇乱子伦视频在线观看| 国产精品人妻久久久影院| 三级毛片av免费| 亚洲成人av在线免费| 日本 av在线| 噜噜噜噜噜久久久久久91| 国产69精品久久久久777片| 伊人久久精品亚洲午夜| 最新中文字幕久久久久| 高清毛片免费观看视频网站| 日韩欧美在线乱码| 亚洲成人中文字幕在线播放| 卡戴珊不雅视频在线播放| 校园春色视频在线观看| 在线a可以看的网站| 3wmmmm亚洲av在线观看| 在线观看美女被高潮喷水网站| 美女高潮的动态| 欧美绝顶高潮抽搐喷水| 日韩中字成人| 夜夜爽天天搞| 亚洲人成网站高清观看| 成人毛片a级毛片在线播放| 九色成人免费人妻av| 国产精品嫩草影院av在线观看| 99精品在免费线老司机午夜| 国产精品久久久久久亚洲av鲁大| 国产精品爽爽va在线观看网站| 99久国产av精品| 国产探花极品一区二区| 一区福利在线观看| 久久午夜福利片| 特大巨黑吊av在线直播| 日本熟妇午夜| 亚洲av.av天堂| 国产片特级美女逼逼视频| 精品久久久久久久人妻蜜臀av| 日本免费一区二区三区高清不卡| 国产一区二区激情短视频| 久久午夜亚洲精品久久| 精品久久久噜噜| 久久热精品热| 中国国产av一级| 校园春色视频在线观看| 亚洲电影在线观看av| 久久中文看片网| 欧美成人一区二区免费高清观看| 乱码一卡2卡4卡精品| 黄色日韩在线| 日本精品一区二区三区蜜桃| 欧美xxxx性猛交bbbb| 国产综合懂色| 亚洲国产精品合色在线| 国产蜜桃级精品一区二区三区| 狂野欧美白嫩少妇大欣赏| 插逼视频在线观看| 99九九线精品视频在线观看视频| 国产视频内射| 国产精品国产高清国产av| 亚洲精品色激情综合| 又爽又黄无遮挡网站| 国产精品一区二区性色av| 国产精品女同一区二区软件| 日本一本二区三区精品| 少妇丰满av| 简卡轻食公司| 免费av不卡在线播放| 听说在线观看完整版免费高清| 高清毛片免费看| 一进一出抽搐gif免费好疼| 久久综合国产亚洲精品| 国产av一区在线观看免费| 国产精品一区二区三区四区免费观看 | 欧美一级a爱片免费观看看| 看十八女毛片水多多多| 少妇人妻一区二区三区视频| 老司机影院成人| 日本熟妇午夜| 国产成人福利小说| 欧洲精品卡2卡3卡4卡5卡区| 免费在线观看成人毛片| 国产伦一二天堂av在线观看| 日韩三级伦理在线观看| 一级av片app| 身体一侧抽搐| 日日摸夜夜添夜夜爱| 成人一区二区视频在线观看| 美女大奶头视频| 午夜爱爱视频在线播放| 波野结衣二区三区在线| 一级毛片久久久久久久久女| 国产 一区 欧美 日韩| av在线观看视频网站免费| 午夜精品在线福利| 看十八女毛片水多多多| 精品久久久久久久久av| 老司机福利观看| 亚洲,欧美,日韩| 综合色av麻豆| 天堂av国产一区二区熟女人妻| 深夜精品福利| 久久草成人影院| 伦理电影大哥的女人| 噜噜噜噜噜久久久久久91| 国产av麻豆久久久久久久| 菩萨蛮人人尽说江南好唐韦庄 | 国产免费男女视频| 国产精品免费一区二区三区在线| 成熟少妇高潮喷水视频| 欧美日本亚洲视频在线播放| 亚洲最大成人手机在线| 搡老熟女国产l中国老女人| 亚洲av五月六月丁香网| 亚洲内射少妇av| 中文字幕免费在线视频6| 又粗又爽又猛毛片免费看| 最近手机中文字幕大全| 久久鲁丝午夜福利片| 有码 亚洲区| 国产又黄又爽又无遮挡在线| 日韩中字成人| 99热这里只有是精品在线观看| 国产精品一区二区性色av| 97热精品久久久久久| 久久久久久久久久成人| 国产精品爽爽va在线观看网站| av在线老鸭窝| 草草在线视频免费看| 非洲黑人性xxxx精品又粗又长| 欧美区成人在线视频| 成人午夜高清在线视频| 国产亚洲精品综合一区在线观看| 五月玫瑰六月丁香| 欧美国产日韩亚洲一区| 深夜a级毛片| 秋霞在线观看毛片| 你懂的网址亚洲精品在线观看 | 寂寞人妻少妇视频99o| 女人十人毛片免费观看3o分钟| 中文字幕av在线有码专区| 丰满人妻一区二区三区视频av| 国产精品久久久久久久久免| 又粗又爽又猛毛片免费看| 日韩高清综合在线| 免费无遮挡裸体视频| 男女边吃奶边做爰视频| 一本精品99久久精品77| 男人舔女人下体高潮全视频| 99热这里只有是精品在线观看| 99久久久亚洲精品蜜臀av| 插阴视频在线观看视频| 少妇高潮的动态图| 激情 狠狠 欧美| 国产欧美日韩精品一区二区| 国产精品,欧美在线| 91精品国产九色| 亚洲精品亚洲一区二区| 美女cb高潮喷水在线观看| 欧美一区二区国产精品久久精品| 国产乱人偷精品视频| 日韩中字成人| 成人鲁丝片一二三区免费| 嫩草影视91久久| 国产真实乱freesex| 在线a可以看的网站| 一个人免费在线观看电影| 国产精品不卡视频一区二区| 国产亚洲91精品色在线| av在线老鸭窝| 91麻豆精品激情在线观看国产| 色av中文字幕| 无遮挡黄片免费观看| 最近2019中文字幕mv第一页| 国产免费一级a男人的天堂| 在线观看午夜福利视频| 成年版毛片免费区| 男女之事视频高清在线观看| av在线亚洲专区| 亚洲精品粉嫩美女一区| 精品人妻一区二区三区麻豆 | 18禁在线无遮挡免费观看视频 | 日韩欧美免费精品| 中文字幕av在线有码专区| 亚洲av免费在线观看| 日本三级黄在线观看| 亚洲成人精品中文字幕电影| 午夜激情福利司机影院| 国内少妇人妻偷人精品xxx网站| 禁无遮挡网站| 伦理电影大哥的女人| 男女之事视频高清在线观看| 免费av观看视频| 国国产精品蜜臀av免费| 观看免费一级毛片| 欧美bdsm另类| 色视频www国产| 亚洲激情五月婷婷啪啪| 亚洲欧美中文字幕日韩二区| 国产精品久久久久久久电影| av卡一久久| 黄色配什么色好看| 免费看美女性在线毛片视频| 97超碰精品成人国产| 国产精品人妻久久久影院| 观看免费一级毛片| 菩萨蛮人人尽说江南好唐韦庄 | 中文字幕av成人在线电影| 国产成人影院久久av| 少妇熟女aⅴ在线视频| 日韩欧美免费精品| 日本一本二区三区精品| 日日撸夜夜添| 亚洲第一电影网av| 搡女人真爽免费视频火全软件 | 欧美日韩国产亚洲二区| 亚洲精品粉嫩美女一区| 国产色婷婷99| av免费在线看不卡| 老女人水多毛片| 91麻豆精品激情在线观看国产| 久久精品国产亚洲av天美| 久久亚洲精品不卡| 亚洲美女搞黄在线观看 | 99热全是精品| 老熟妇仑乱视频hdxx| 亚洲欧美中文字幕日韩二区| 中文亚洲av片在线观看爽| 毛片一级片免费看久久久久| 亚洲av五月六月丁香网| 免费人成视频x8x8入口观看| 亚洲最大成人中文| 观看美女的网站| 91狼人影院| 狂野欧美激情性xxxx在线观看| 久久久久久久久中文| 九九热线精品视视频播放| 美女被艹到高潮喷水动态| 我的女老师完整版在线观看| 日本三级黄在线观看| 久久亚洲精品不卡| 日本在线视频免费播放| 在线观看一区二区三区| 亚洲av电影不卡..在线观看| 亚洲精品成人久久久久久| 一级av片app| eeuss影院久久| 国产91av在线免费观看| 精品久久久久久久久亚洲| 极品教师在线视频| 欧美日韩精品成人综合77777| 高清毛片免费看| 免费av毛片视频| 国产在视频线在精品| 美女黄网站色视频| 久久久久久久亚洲中文字幕| 国产精品一及| 久久久久久久久久久丰满| 在线观看一区二区三区| 久久精品国产亚洲av天美| 亚洲一级一片aⅴ在线观看| 久久久久久久亚洲中文字幕| 国产av不卡久久| 在线看三级毛片| 中文字幕人妻熟人妻熟丝袜美| 美女黄网站色视频| 联通29元200g的流量卡| 久久久精品94久久精品| 国产伦一二天堂av在线观看| 99久久无色码亚洲精品果冻| 三级男女做爰猛烈吃奶摸视频| 亚洲欧美清纯卡通| 三级国产精品欧美在线观看| 国产片特级美女逼逼视频| 亚洲av中文av极速乱| 免费看av在线观看网站| 97人妻精品一区二区三区麻豆| 欧美高清性xxxxhd video| 啦啦啦韩国在线观看视频| 久久久久久久久大av| 国产成人a区在线观看| 国产私拍福利视频在线观看| 老师上课跳d突然被开到最大视频| 亚洲av美国av| 可以在线观看毛片的网站| 精品午夜福利在线看| 精品久久久噜噜| 噜噜噜噜噜久久久久久91| 伊人久久精品亚洲午夜| 久久综合国产亚洲精品| 国产精品乱码一区二三区的特点| 美女内射精品一级片tv| av.在线天堂| 国产精品美女特级片免费视频播放器| 日韩精品青青久久久久久| 国产69精品久久久久777片| 一级a爱片免费观看的视频| 校园春色视频在线观看| 人人妻人人澡欧美一区二区| 女的被弄到高潮叫床怎么办| 久久99热这里只有精品18| 淫妇啪啪啪对白视频| 国产黄a三级三级三级人| 国产亚洲精品综合一区在线观看| 少妇裸体淫交视频免费看高清| 亚洲色图av天堂| 国产精华一区二区三区| 亚洲激情五月婷婷啪啪| 欧美成人精品欧美一级黄| 日日撸夜夜添| 国产av麻豆久久久久久久| 一级毛片久久久久久久久女| 看十八女毛片水多多多| 免费观看的影片在线观看| 日韩精品青青久久久久久| 女的被弄到高潮叫床怎么办| 亚洲一级一片aⅴ在线观看| 小蜜桃在线观看免费完整版高清| 一个人免费在线观看电影| av天堂中文字幕网| 在现免费观看毛片| 日本与韩国留学比较| 色尼玛亚洲综合影院| 99在线人妻在线中文字幕| 欧美+日韩+精品|